Ergomed H1 2023 Trading Update
25/07/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230725:nRSY0287Ha&default-theme=true
RNS Number : 0287H Ergomed plc 25 July 2023
PRESS RELEASE
Ergomed H1 2023 Trading Update
Strong, resilient H1 performance: solid growth and positive outlook
· Robust revenue growth of 10% over H1 2022 to £76.7 million
· Strong order book of £310 million with growth of 9% year over
year (11% adjusting for foreign exchange) providing excellent visibility into
H2 2023 and beyond
· New business pipeline growth of 30% over H1 2022 reflecting the
benefits of commercial investments
· Revenue and adjusted EBITDA for full year 2023 anticipated to be
in line with market expectations
· Debt free with available facilities of up to £80.0 million to
support future strategic M&A
Guildford, UK - 25 July 2023: Ergomed plc (LSE: ERGO) ("Ergomed" or the
"Company"), a company focused on providing specialised services to the
pharmaceutical industry, today announces a trading update for the first half
of 2023. The Company will provide further details on the first half
performance in its interim results in September 2023.
Strong and resilient trading in H1 2023 with a positive outlook
Ergomed continues to demonstrate its resilience and increasingly competitive
strength, as shown by a strong first half of 2023, with revenue of £76.7
million (H1 2022: £69.9 million), an increase of 10% (7% in constant
currency) over H1 2022. The Clinical Research Services (CRO) business
increased its revenue by 11% (8% in constant currency) to £38.0 million from
£34.3 million in H1 2022. PrimeVigilance, the pharmacovigilance (PV)
business, increased its revenue by 9% (6% in constant currency) to £38.7
million from £35.6 million in H1 2022.
Cash at 30 June 2023 was £26.0 million (H1 2022: £12.0 million), with good
underlying operating cash flow generation during the period. The Company
remains in a robust financial position, debt free, with a strong balance
sheet, and unutilised facilities of up to £80.0 million to support continued
expansion both organically and through acquisitions.
Revenue and adjusted EBITDA for the full year 2023 are anticipated to be in
line with market expectations, demonstrating the Company's resilience and
ability to maintain its strong financial performance despite the continued
challenging macro-economic environment.
Strong pipeline and order book growth with excellent forward visibility
Ergomed's order book continues to grow reaching £310 million at the end of H1
2023, an increase of 9% on the prior year (H1 2022: £284 million) or 11%
adjusting for foreign exchange. This provides excellent visibility of revenue
for the second half of 2023 and beyond and is supported by robust new business
pipeline growth of 30% over H1 2022.
Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented:
"Ergomed has made a very solid start to the year demonstrating continued
growth, reflecting the resilience of the markets we operate in, our
services-based business model, and the global appeal of our offering to our
clients. We continue to execute on our strategy to transform the business by
investing in technology and our commercial infrastructure which has been
reflected in robust year over year growth of our new business pipeline. In
addition, we continue to focus on prudent cost management across the Company,
and executing our disciplined approach to M&A. We expect to deliver on our
expectations for financial results for 2023, and we look forward with
confidence to the rest of this year and beyond."
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Jonathan Curtain (Chief Financial Officer)
Keith Byrne (Senior Vice President, Capital Markets & Strategy)
Numis (Nominated Advisor and Joint Broker) Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown / Jack McLaren
Peel Hunt (Joint Broker) Tel: +44 (0) 20 7418 8852
James Steel / Dr. Christopher Golden
Consilium Strategic Communications - for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TSTUSURROBUBUUR